Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis

Koji Takemoto, Yutaka Yamamoto, Yutaka Ueda, Yoshihiro Sumita, Koichiro Yoshida, Yoshihito Niki

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus. Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded. Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg). Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.

Original languageEnglish
Pages (from-to)311-317
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 1 2004
Externally publishedYes

Fingerprint

Aspergillosis
Amphotericin B
Aspergillus
Maximum Tolerated Dose
Intravenous Injections
liposomal amphotericin B
Tail
Veins
Control Groups
Infection

Keywords

  • Amphotericin B deoxycholate
  • Aspergillus
  • Liposomal amphotericin B
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. / Takemoto, Koji; Yamamoto, Yutaka; Ueda, Yutaka; Sumita, Yoshihiro; Yoshida, Koichiro; Niki, Yoshihito.

In: Journal of Antimicrobial Chemotherapy, Vol. 53, No. 2, 01.02.2004, p. 311-317.

Research output: Contribution to journalArticle

Takemoto, Koji ; Yamamoto, Yutaka ; Ueda, Yutaka ; Sumita, Yoshihiro ; Yoshida, Koichiro ; Niki, Yoshihito. / Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. In: Journal of Antimicrobial Chemotherapy. 2004 ; Vol. 53, No. 2. pp. 311-317.
@article{90f232b2bfc2430ebe4e7352c2a0c34d,
title = "Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis",
abstract = "Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus. Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded. Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg). Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.",
keywords = "Amphotericin B deoxycholate, Aspergillus, Liposomal amphotericin B, Tolerability",
author = "Koji Takemoto and Yutaka Yamamoto and Yutaka Ueda and Yoshihiro Sumita and Koichiro Yoshida and Yoshihito Niki",
year = "2004",
month = "2",
day = "1",
doi = "10.1093/jac/dkh055",
language = "English",
volume = "53",
pages = "311--317",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis

AU - Takemoto, Koji

AU - Yamamoto, Yutaka

AU - Ueda, Yutaka

AU - Sumita, Yoshihiro

AU - Yoshida, Koichiro

AU - Niki, Yoshihito

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus. Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded. Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg). Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.

AB - Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus. Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded. Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg). Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.

KW - Amphotericin B deoxycholate

KW - Aspergillus

KW - Liposomal amphotericin B

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=1242285169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242285169&partnerID=8YFLogxK

U2 - 10.1093/jac/dkh055

DO - 10.1093/jac/dkh055

M3 - Article

C2 - 14729753

AN - SCOPUS:1242285169

VL - 53

SP - 311

EP - 317

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -